The process of ECT includes creating a widespread seizure that results in stiffness and rigidity of muscles, followed by repetitive jerking movements. Absence seizures cause a brief period of unconsciousness, while atonic seizures lead to a loss of muscle tone.

DBS, a type of neurosurgery, is typically conducted in an operating theatre and has been shown to be effective in treating OCD based on randomized controlled trial (RCT) data. However, there are currently no NICE Guidelines available for DBS.

Neurostimulation is a treatment that uses electromagnetic energy targeted at the brain. There are several forms of neurostimulation, including TMS, deep brain stimulation, and ECT. TMS is a non-invasive, non-convulsive technique used to stimulate neural tissue. It involves the placement of an electromagnetic coil on the patient’s scalp to deliver a short, powerful magnetic field pulse through the scalp and induce electric current in the brain. TMS is used to treat depression when standard treatments have failed. Deep brain stimulation is a neurosurgical technique that involves placing an electrode within the brain to deliver a high-frequency current in a specific subcortical of deep cortical structure. It has been used to treat Parkinson’s, dysthymia, OCD, and Tourette syndrome. There is RCT evidence to demonstrate its effectiveness in OCD, but conflicting results in depression and Tourette’s. DBS is also being trailed in other conditions such as anorexia, bipolar, and additions.

The Care Program Approach (CPA) was implemented in 1991 to enhance community care for individuals with severe mental illness. The CPA comprises four primary components, including assessment, a care plan, a Care Coordinator (formerly known as a Key Worker), and regular review. There are two levels of CPA, namely standard and enhanced. Standard care plans are suitable for individuals who require minimal input from a single agency and pose minimal risk to themselves of others. Enhanced care plans are designed for individuals with complex needs who require collaboration among multiple agencies.

This intervention is designed to prevent depression in a broad population, making it applicable to everyone and can be categorized as either a universal of primary prevention strategy.

Prevention measures can be classified into different levels, depending on the stage at which they are implemented. The first model, developed in the 1960s, includes primary, secondary, and tertiary prevention. Primary prevention aims to intervene before a disease of problem begins, and can be universal (targeted to the general public), selective (targeted to a high-risk population), of indicated (targeted to individuals with minimal but detectable signs of a disorder). Secondary prevention aims to detect and treat disease that has not yet become symptomatic, while tertiary prevention involves the care of established disease.

A newer model, developed in 1992, focuses on prevention interventions used before the initial onset of a disorder. This model also includes three levels: universal prevention (targeted to the general population), selective prevention (targeted to a high-risk population), and indicated prevention (targeted to individuals with minimal but detectable signs of a disorder). Examples of prevention measures include cognitive interventions for adolescents with cognitive deficits to prevent the later phases of schizophrenia, screening procedures for early detection and treatment of disease, and the use of low-dose atypical antipsychotics and CBT for patients with prodromal symptoms of schizophrenia to delay of prevent disease onset.

Electroconvulsive therapy (ECT) is known to cause retrograde amnesia, which is the most persistent cognitive side effect (Lisanby, 2000). Patients often experience memory gaps for events that occurred around the time of ECT, and sometimes even for events that happened months of years prior. While retrograde amnesia typically improves within a few months after treatment, some patients may not fully recover and may have permanent memory loss for events close to the time of treatment. Additionally, anterograde amnesia may also be a possible side effect.

ECT (Treatment) – Summary of Effectiveness and Recommendations

ECT (Electroconvulsive Therapy) is a treatment that induces a therapeutic seizure through the application of electrical current under general anesthesia and muscle relaxation. It is prescribed as a course and is usually administered twice weekly for 6 to 12 treatments. ECT is the most effective short-term treatment for major depression, with remission rates of around 60-80% when used as first-line treatment in a severe depressive episode. However, without maintenance treatment, the relapse rate is extremely high (over 80%) in the 6 months after successful ECT.

Cognitive effects are the main limitation to the wider use of ECT, particularly acute confusion shortly after the treatment, retrograde amnesia, and some losses in autobiographical memory longer term. The current state of evidence does not allow the general use of ECT in the management of schizophrenia. Bilateral ECT is more effective than unilateral ECT but may cause more cognitive impairment. With unilateral ECT, a higher stimulus dose is associated with greater efficacy but also increased cognitive impairment compared with a lower stimulus dose.

NICE (National Institute for Health and Care Excellence) recommends that ECT is used only to achieve rapid and short-term improvement of severe symptoms after an adequate trial of other treatment options has proven ineffective and/of when the condition is considered to be potentially life-threatening. ECT is recommended for individuals with severe depression (that is life-threatening and when a rapid response is required, of when other treatments have failed), moderate depression (consider it if their depression has not responded to multiple drug treatments and psychological treatment), catatonia, and a prolonged of severe manic episode.

The RCPsych (Royal College of Psychiatrists) position on ECT recommends it as a first-line treatment for individuals with high suicidal risk, severe psychomotor retardation and associated problems of compromised eating and drinking and/of physical deterioration, treatment-resistant depression that has responded to ECT in a previous episode of illness, pregnant individuals with severe depression, of severe mixed affective states, mania of catatonia and whose physical health of that of the fetus is at serious risk, and those who prefer this form of treatment. ECT is recommended as a second-line treatment for individuals with treatment-resistant depression, severe side-effects from medication, and persistent of life-threatening symptoms in severe of prolonged mania. ECT is indicated in some circumstances for individuals with bipolar depression, postnatal psychosis, treatment-resistant schizophrenia, treatment-resistant catatonia, and frequent relapses and recurrences of depression (maintenance).

In May 2014, the UK implemented a ban on selling alcohol below the cost of duty and VAT, known as below-cost selling. According to researchers at the University of Sheffield, this ban is expected to result in the prevention of 14 deaths and 500 hospital admissions each year in England.

Research has consistently shown that out-patient services, whether they are general of specialized eating disorder clinics, are more likely to be cost-effective than in-patient care. The majority of patients with eating disorders can be effectively managed in out-patient clinics, with only a small percentage requiring in-patient care. When comparing outpatient treatment models, including general child and adolescent mental health services, with in-patient treatment, there were significant improvements in all groups at different points during follow-up, with no significant differences between the two types of treatment. The availability of out-patient care is associated with a lower rate of admission to inpatient units. Clinically and economically, lengthy in-patient stays are not recommended, as they are associated with worse outcomes, particularly when they disrupt the patient’s life, such as their work, studies, of time away from family.

The advancements in technology and the widespread availability of smartphones and internet access can be utilized to improve patient care and equip clinicians with more tools for diagnosing and treating mental illnesses. One promising approach is avatar therapy, which has shown positive results in treating auditory hallucinations in patients who did not respond well to medication. Additionally, automated objective behavioral analysis has been used to monitor and predict mood and emotional responses. However, online cognitive behavioral therapy has not been found to be effective in treating auditory hallucinations. Personal Zen is a mobile and tablet app that gamifies techniques proven to be helpful in managing anxiety and stress. Finally, virtual reality exposure therapy has been used to treat post-traumatic stress disorder.

While ECT may be considered for moderate depression in certain cases, it should not be administered if it goes against a legally binding advance decision of directive.

ECT (Treatment) – Summary of Effectiveness and Recommendations

ECT (Electroconvulsive Therapy) is a treatment that induces a therapeutic seizure through the application of electrical current under general anesthesia and muscle relaxation. It is prescribed as a course and is usually administered twice weekly for 6 to 12 treatments. ECT is the most effective short-term treatment for major depression, with remission rates of around 60-80% when used as first-line treatment in a severe depressive episode. However, without maintenance treatment, the relapse rate is extremely high (over 80%) in the 6 months after successful ECT.

Cognitive effects are the main limitation to the wider use of ECT, particularly acute confusion shortly after the treatment, retrograde amnesia, and some losses in autobiographical memory longer term. The current state of evidence does not allow the general use of ECT in the management of schizophrenia. Bilateral ECT is more effective than unilateral ECT but may cause more cognitive impairment. With unilateral ECT, a higher stimulus dose is associated with greater efficacy but also increased cognitive impairment compared with a lower stimulus dose.

NICE (National Institute for Health and Care Excellence) recommends that ECT is used only to achieve rapid and short-term improvement of severe symptoms after an adequate trial of other treatment options has proven ineffective and/of when the condition is considered to be potentially life-threatening. ECT is recommended for individuals with severe depression (that is life-threatening and when a rapid response is required, of when other treatments have failed), moderate depression (consider it if their depression has not responded to multiple drug treatments and psychological treatment), catatonia, and a prolonged of severe manic episode.

The RCPsych (Royal College of Psychiatrists) position on ECT recommends it as a first-line treatment for individuals with high suicidal risk, severe psychomotor retardation and associated problems of compromised eating and drinking and/of physical deterioration, treatment-resistant depression that has responded to ECT in a previous episode of illness, pregnant individuals with severe depression, of severe mixed affective states, mania of catatonia and whose physical health of that of the fetus is at serious risk, and those who prefer this form of treatment. ECT is recommended as a second-line treatment for individuals with treatment-resistant depression, severe side-effects from medication, and persistent of life-threatening symptoms in severe of prolonged mania. ECT is indicated in some circumstances for individuals with bipolar depression, postnatal psychosis, treatment-resistant schizophrenia, treatment-resistant catatonia, and frequent relapses and recurrences of depression (maintenance).

Capsulotomy is a procedure that creates lesions on both sides of the anterior limb of the internal capsule and is commonly used to treat OCD and depression. Cingulotomy is another procedure used to treat refractory anxiety, pain, depression, and OCD. SST is primarily used for depression but can also be used for anxiety and OCD. Limbic leucopathy is a combination of SST and cingulotomy and is used to treat depression, anxiety, and OCD. Although amygdalotomy was originally developed to treat aggression, it is now rarely used.

Non-Pharmacological Interventions for Treatment-Resistant Depression

One non-pharmacological intervention for treatment-resistant depression is repetitive transcranial magnetic stimulation (rTMS). This outpatient procedure involves using an electromagnetic coil to induce electric currents in the cerebral cortex without the need for anesthesia. It is typically used for patients who have not responded to antidepressant medication of for whom antidepressants are not suitable. Treatment can be delivered unilaterally or bilaterally and lasts for 2 to 6 weeks.

Electroconvulsive therapy (ECT) is another option for treatment-resistant depression, but it is associated with adverse effects such as autobiographical retrograde memory loss. It is not recommended for patients who have recently had a heart attack and are keen to avoid side effects.

Psychosurgery is rarely used and only as a last resort for severely debilitating mental illness. It is associated with seizures and permanent cognitive impairment.

Deep brain stimulation (DBS) is a controversial option for treatment-resistant depression. It involves targeting specific areas of the brain, such as the subcallosal cingulate and medial forebrain bundle. However, it is not currently recommended by NICE and is more commonly used for Parkinson’s disorder.

Lithium may also be an option, but the question specifically asks for non-pharmacological interventions.

ECT (Treatment) – Summary of Effectiveness and Recommendations

ECT (Electroconvulsive Therapy) is a treatment that induces a therapeutic seizure through the application of electrical current under general anesthesia and muscle relaxation. It is prescribed as a course and is usually administered twice weekly for 6 to 12 treatments. ECT is the most effective short-term treatment for major depression, with remission rates of around 60-80% when used as first-line treatment in a severe depressive episode. However, without maintenance treatment, the relapse rate is extremely high (over 80%) in the 6 months after successful ECT.

Cognitive effects are the main limitation to the wider use of ECT, particularly acute confusion shortly after the treatment, retrograde amnesia, and some losses in autobiographical memory longer term. The current state of evidence does not allow the general use of ECT in the management of schizophrenia. Bilateral ECT is more effective than unilateral ECT but may cause more cognitive impairment. With unilateral ECT, a higher stimulus dose is associated with greater efficacy but also increased cognitive impairment compared with a lower stimulus dose.

NICE (National Institute for Health and Care Excellence) recommends that ECT is used only to achieve rapid and short-term improvement of severe symptoms after an adequate trial of other treatment options has proven ineffective and/of when the condition is considered to be potentially life-threatening. ECT is recommended for individuals with severe depression (that is life-threatening and when a rapid response is required, of when other treatments have failed), moderate depression (consider it if their depression has not responded to multiple drug treatments and psychological treatment), catatonia, and a prolonged of severe manic episode.

The RCPsych (Royal College of Psychiatrists) position on ECT recommends it as a first-line treatment for individuals with high suicidal risk, severe psychomotor retardation and associated problems of compromised eating and drinking and/of physical deterioration, treatment-resistant depression that has responded to ECT in a previous episode of illness, pregnant individuals with severe depression, of severe mixed affective states, mania of catatonia and whose physical health of that of the fetus is at serious risk, and those who prefer this form of treatment. ECT is recommended as a second-line treatment for individuals with treatment-resistant depression, severe side-effects from medication, and persistent of life-threatening symptoms in severe of prolonged mania. ECT is indicated in some circumstances for individuals with bipolar depression, postnatal psychosis, treatment-resistant schizophrenia, treatment-resistant catatonia, and frequent relapses and recurrences of depression (maintenance).

The recovery model raises questions about how to define recovery from a mental health problem. Mental health services tend to define recovery based on measures such as symptom remission, hospitalization, independence, and involvement in work of school. However, people with mental health problems define recovery differently, placing importance on factors such as overcoming the effects of being a patient, establishing a fulfilling life and positive identity, and discovering how to live well with enduring symptoms.

In essence, the most appropriate term to describe this intervention is tertiary prevention since universal, indicated, and selective prevention strategies target individuals before the onset of a full-blown illness.

Prevention measures can be classified into different levels, depending on the stage at which they are implemented. The first model, developed in the 1960s, includes primary, secondary, and tertiary prevention. Primary prevention aims to intervene before a disease of problem begins, and can be universal (targeted to the general public), selective (targeted to a high-risk population), of indicated (targeted to individuals with minimal but detectable signs of a disorder). Secondary prevention aims to detect and treat disease that has not yet become symptomatic, while tertiary prevention involves the care of established disease.

A newer model, developed in 1992, focuses on prevention interventions used before the initial onset of a disorder. This model also includes three levels: universal prevention (targeted to the general population), selective prevention (targeted to a high-risk population), and indicated prevention (targeted to individuals with minimal but detectable signs of a disorder). Examples of prevention measures include cognitive interventions for adolescents with cognitive deficits to prevent the later phases of schizophrenia, screening procedures for early detection and treatment of disease, and the use of low-dose atypical antipsychotics and CBT for patients with prodromal symptoms of schizophrenia to delay of prevent disease onset.

According to a study conducted by the University of Sheffield, implementing a minimum unit price of 45 pence for alcohol could potentially save 624 lives and prevent 237,000 hospital admissions in England every year. Additionally, the research suggests that the ban on selling alcohol below cost, which was implemented in May 2014, could prevent 14 deaths and 500 hospital admissions annually.

Guidance for Registered Medical Practitioners on the Notification of Deaths Regulations 2019

For informal patients in psychiatric hospital, there is no automatic statutory requirement to inform the senior coroner. However, if another criterion is fulfilled, such as death due to poisoning, violence of trauma, self-harm, neglect, medical procedure, employment-related injury of disease, unnatural death, unknown cause of death, death in custody, of unknown identity of the deceased, then the coroner should be informed. It is important to note that there is no requirement to notify the coroner for those subject to DOLS. This national guidance replaces any local protocols.

The study by Brown and Harris explores the societal factors that contribute to the development of depression.

Model for Identifying Pathways to Psychiatric Care

Goldberg and Huxley (1992) proposed a model that can be used to examine the identification, assessment, and pathway to psychiatric care for individuals with common mental health disorders. The model consists of five levels of care, with filters between them that are influenced by the behavior of those with the disorders and the healthcare practitioners they encounter. The authors highlight that only a small percentage of individuals with mental disorders receive specialized psychiatric care.

DBS can lead to various complications, such as intracranial bleeding (which occurs in around 2.0-2.5% of implants), dislocation, lead fracture, and infection. Additionally, stimulation-induced adverse side effects may include paraesthesia, tonic muscle contractions, dyskinesia, and gait ataxia. While less common, some individuals may experience side effects such as aggression, mirthful laughter, depression, penile erection, of mania.

The individuals being focused on already exhibit early signs, making this a suitable approach for indicated prevention.

Prevention measures can be classified into different levels, depending on the stage at which they are implemented. The first model, developed in the 1960s, includes primary, secondary, and tertiary prevention. Primary prevention aims to intervene before a disease of problem begins, and can be universal (targeted to the general public), selective (targeted to a high-risk population), of indicated (targeted to individuals with minimal but detectable signs of a disorder). Secondary prevention aims to detect and treat disease that has not yet become symptomatic, while tertiary prevention involves the care of established disease.

A newer model, developed in 1992, focuses on prevention interventions used before the initial onset of a disorder. This model also includes three levels: universal prevention (targeted to the general population), selective prevention (targeted to a high-risk population), and indicated prevention (targeted to individuals with minimal but detectable signs of a disorder). Examples of prevention measures include cognitive interventions for adolescents with cognitive deficits to prevent the later phases of schizophrenia, screening procedures for early detection and treatment of disease, and the use of low-dose atypical antipsychotics and CBT for patients with prodromal symptoms of schizophrenia to delay of prevent disease onset.

Prevention measures can be classified into different levels, depending on the stage at which they are implemented. The first model, developed in the 1960s, includes primary, secondary, and tertiary prevention. Primary prevention aims to intervene before a disease of problem begins, and can be universal (targeted to the general public), selective (targeted to a high-risk population), of indicated (targeted to individuals with minimal but detectable signs of a disorder). Secondary prevention aims to detect and treat disease that has not yet become symptomatic, while tertiary prevention involves the care of established disease.

A newer model, developed in 1992, focuses on prevention interventions used before the initial onset of a disorder. This model also includes three levels: universal prevention (targeted to the general population), selective prevention (targeted to a high-risk population), and indicated prevention (targeted to individuals with minimal but detectable signs of a disorder). Examples of prevention measures include cognitive interventions for adolescents with cognitive deficits to prevent the later phases of schizophrenia, screening procedures for early detection and treatment of disease, and the use of low-dose atypical antipsychotics and CBT for patients with prodromal symptoms of schizophrenia to delay of prevent disease onset.

For individuals diagnosed with chronic psychosis, the DVLA mandates a minimum of 3 months of stability before they can resume driving standard cars and motorcycles. However, for those driving LGVs of PCVs, this period is extended to 3 years. Similar guidelines apply to those with acute psychotic disorders and hypomania/mania. In the case of severe anxiety of depression, LGV/PCV drivers may be allowed to resume driving after 6 months of stability.

Given the patient’s improved psychotic symptoms, an extended stay in an acute ward would not be beneficial. However, due to ongoing substance misuse and challenging behaviors, discharge from the hospital is not yet possible. While an addictions admission of transfer to a forensic ward is not necessary, a rehabilitation psychiatry ward would be the most appropriate next step. This would provide the patient with the necessary support to address their substance misuse and challenging behaviors, while also promoting their skills and independence for a successful return to community living.

If there is a dispute regarding the recent diagnosis, it would be best for the patient to seek a second opinion assessment. During this time, it is recommended that the patient refrains from driving. It is the responsibility of the license holder to inform the DVLA of any changes in their medical condition that may affect their ability to drive safely. Patients should be informed of any conditions that may impact their driving ability and their legal obligation to inform the DVLA. The GMC has provided clear guidance for situations where a license holder is unwilling or unable to inform the DVLA. If a doctor is unable to convince a patient to stop driving of discovers that the patient is driving against their advice, they should immediately contact the DVLA and provide any relevant information in confidence to the medical adviser. Before contacting the DVLA, the patient should be advised and informed in writing after contact has been made. It is not appropriate to breach confidentiality by speaking to the patient’s family without their consent.

The ECTAS Guidelines 2019 recommend a frequency of two times per week.

ECT (Treatment) – Summary of Effectiveness and Recommendations

ECT (Electroconvulsive Therapy) is a treatment that induces a therapeutic seizure through the application of electrical current under general anesthesia and muscle relaxation. It is prescribed as a course and is usually administered twice weekly for 6 to 12 treatments. ECT is the most effective short-term treatment for major depression, with remission rates of around 60-80% when used as first-line treatment in a severe depressive episode. However, without maintenance treatment, the relapse rate is extremely high (over 80%) in the 6 months after successful ECT.

Cognitive effects are the main limitation to the wider use of ECT, particularly acute confusion shortly after the treatment, retrograde amnesia, and some losses in autobiographical memory longer term. The current state of evidence does not allow the general use of ECT in the management of schizophrenia. Bilateral ECT is more effective than unilateral ECT but may cause more cognitive impairment. With unilateral ECT, a higher stimulus dose is associated with greater efficacy but also increased cognitive impairment compared with a lower stimulus dose.

NICE (National Institute for Health and Care Excellence) recommends that ECT is used only to achieve rapid and short-term improvement of severe symptoms after an adequate trial of other treatment options has proven ineffective and/of when the condition is considered to be potentially life-threatening. ECT is recommended for individuals with severe depression (that is life-threatening and when a rapid response is required, of when other treatments have failed), moderate depression (consider it if their depression has not responded to multiple drug treatments and psychological treatment), catatonia, and a prolonged of severe manic episode.

The RCPsych (Royal College of Psychiatrists) position on ECT recommends it as a first-line treatment for individuals with high suicidal risk, severe psychomotor retardation and associated problems of compromised eating and drinking and/of physical deterioration, treatment-resistant depression that has responded to ECT in a previous episode of illness, pregnant individuals with severe depression, of severe mixed affective states, mania of catatonia and whose physical health of that of the fetus is at serious risk, and those who prefer this form of treatment. ECT is recommended as a second-line treatment for individuals with treatment-resistant depression, severe side-effects from medication, and persistent of life-threatening symptoms in severe of prolonged mania. ECT is indicated in some circumstances for individuals with bipolar depression, postnatal psychosis, treatment-resistant schizophrenia, treatment-resistant catatonia, and frequent relapses and recurrences of depression (maintenance).

The recovery model raises questions about how to define recovery from a mental health problem. Mental health services tend to define recovery based on measures such as symptom remission, hospitalization, independence, and involvement in work of school. However, people with mental health problems define recovery differently, placing importance on factors such as overcoming the effects of being a patient, establishing a fulfilling life and positive identity, and discovering how to live well with enduring symptoms.

ECT and Seizure Duration: Effect of Psychotropics

On the whole, most drugs do not interfere with ECT. However, it is important to note the effect of psychotropics on seizure duration. The table below summarizes the effect of important psychotropics and their advice:

Psychotropic class: Benzodiazepine
Effect on seizure duration: Reduced
Advice: Avoid where possible

Psychotropic class: SSRIs
Effect on seizure duration: Minimal effect

Psychotropic class: Venlafaxine
Effect on seizure duration: Minimal effect

Psychotropic class: TCAs
Effect on seizure duration: Possibly increased
Advice: TCAs are associated with arrhythmia following ECT in the elderly and those with cardiac disease, so they should be avoided in ECT in these groups.

Psychotropic class: MAOIs
Effect on seizure duration: Minimal effect

Psychotropic class: Lithium
Effect on seizure duration: Possibly increased
Advice: Generally used in ECT without significant problems.

Psychotropic class: Antipsychotics
Effect on seizure duration: Some potential increase in clozapine and phenothiazines, other antipsychotics considered ok
Advice: Limited data.

Psychotropic class: Anticonvulsants
Effect on seizure duration: Reduced
Advice: If used as a mood stabilizer, continue but be prepared to use higher energy stimulus.

(Source: Maudsley Guidelines 10th Edition, p.187)

ECT (Treatment) – Summary of Effectiveness and Recommendations

ECT (Electroconvulsive Therapy) is a treatment that induces a therapeutic seizure through the application of electrical current under general anesthesia and muscle relaxation. It is prescribed as a course and is usually administered twice weekly for 6 to 12 treatments. ECT is the most effective short-term treatment for major depression, with remission rates of around 60-80% when used as first-line treatment in a severe depressive episode. However, without maintenance treatment, the relapse rate is extremely high (over 80%) in the 6 months after successful ECT.

Cognitive effects are the main limitation to the wider use of ECT, particularly acute confusion shortly after the treatment, retrograde amnesia, and some losses in autobiographical memory longer term. The current state of evidence does not allow the general use of ECT in the management of schizophrenia. Bilateral ECT is more effective than unilateral ECT but may cause more cognitive impairment. With unilateral ECT, a higher stimulus dose is associated with greater efficacy but also increased cognitive impairment compared with a lower stimulus dose.

NICE (National Institute for Health and Care Excellence) recommends that ECT is used only to achieve rapid and short-term improvement of severe symptoms after an adequate trial of other treatment options has proven ineffective and/of when the condition is considered to be potentially life-threatening. ECT is recommended for individuals with severe depression (that is life-threatening and when a rapid response is required, of when other treatments have failed), moderate depression (consider it if their depression has not responded to multiple drug treatments and psychological treatment), catatonia, and a prolonged of severe manic episode.

The RCPsych (Royal College of Psychiatrists) position on ECT recommends it as a first-line treatment for individuals with high suicidal risk, severe psychomotor retardation and associated problems of compromised eating and drinking and/of physical deterioration, treatment-resistant depression that has responded to ECT in a previous episode of illness, pregnant individuals with severe depression, of severe mixed affective states, mania of catatonia and whose physical health of that of the fetus is at serious risk, and those who prefer this form of treatment. ECT is recommended as a second-line treatment for individuals with treatment-resistant depression, severe side-effects from medication, and persistent of life-threatening symptoms in severe of prolonged mania. ECT is indicated in some circumstances for individuals with bipolar depression, postnatal psychosis, treatment-resistant schizophrenia, treatment-resistant catatonia, and frequent relapses and recurrences of depression (maintenance).

In May 2014, the UK implemented a ban on selling alcohol below the cost of duty and VAT, known as below-cost selling. Prior to the ban, only 0.7% of all units sold were estimated to be sold below duty plus VAT. A recent study by the University of Sheffield suggests that the ban will prevent 14 deaths and 500 hospital admissions annually in England. However, if the ban had been set at a higher price point, between 40 pence and 50 pence per unit, the impact would have been much greater, preventing 624 deaths and 23,700 admissions, and affecting almost a quarter (23.2%) of all alcohol units sold.

Institutional Racism in Psychiatry

There has been growing concern that institutional racism may be contributing to the overrepresentation of Black patients in mental health settings. Despite ethnic minorities making up only 9% of the UK population, the 2010 ‘Count me in Census’ found that 23% of inpatients and those on CTOs were from Black and minority ethnic groups. Black minority groups also had higher rates of admission, detention, and seclusion.

While patient factors, such as higher rates of mental illness in Black minority groups, may contribute to these findings, there is also a suggestion of inherent racism within psychiatry. This may manifest in perceptions of Black and minority ethnic patients being at greater risk, as well as systemic factors that disadvantage these groups.

It is important to address these issues and work towards a more equitable and just mental health system for all patients, regardless of their ethnicity.

If a patient’s plasma clozapine to norclozapine ratio decreases while on a consistent clozapine dose, it may indicate enzyme induction. Conversely, an increase in the ratio may suggest enzyme inhibition of saturation, recent non-trough sample, of poor compliance. The clozapine to norclozapine ratio is typically stable among patients with stable clozapine doses.